A recently approved treatment for acute myeloid leukemia (AML) is intended for use along with a companion diagnostic in patients who also receive chemotherapy.
Midostaurin was approved for patients newly diagnosed with AML who have the fms-like tyrosine kinase 3 (FLT3) mutation, as detected by the LeukoStrat CDx FLT3 Mutation Assay. The drug is not indicated as a single-agent induction therapy for patients with AML. Marketed as Rydapt, the drug also was approved for adults with other rare blood disorders—aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, and mast cell leukemia.
Voelker R. New AML Therapy and Diagnostic. JAMA. 2017;317(21):2157. doi:10.1001/jama.2017.6304
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: